EOR Blueprint Update · 2026

Internal Medicine EOR: 2026 blueprint changes

The PAEA Internal Medicine EOR shifts weight into endocrine, neurologic, and renal/genitourinary content for 2026, adds a Professional Practice task area, and drops its standalone Critical Care content area.

When it takes effect

The updated exams are effective as of July 27, 2026; legacy versions remain available through July 2027, so programs can transition on their own timeline.

A new Professional Practice task area (7%) was added to this exam (Health Maintenance is retained).

Internal Medicine EOR blueprint: content areas (2026)

PAEA builds the Internal Medicine End of Rotation exam on a 100-question grid: each scored question sits in one clinical content area and one task area. You will sit 120 questions, because PAEA adds 20 unscored pretest questions. These are the content areas and their published weights.

Content area (clinical)Share of the exam
Cardiovascular20%
Pulmonary15%
Gastrointestinal12%
Endocrine10%
Neurologic10%
Renal/Genitourinary10%
Rheumatologic/Musculoskeletal8%
Hematologic5%
Infectious Diseases5%
Psychiatric/Behavioral Health5%

PAEA's Internal Medicine blueprint (PDF) · topic list (PDF)

Task-area weightings: old vs 2026

Task areas are the medical-knowledge categories every Internal Medicine EOR question is written against. Here is how they shift for 2026:

Task area (medical knowledge)Old2026
History & Physical15%15%
Diagnostic Studies10%14% ↑
Diagnosis25%22% ↓
Health Maintenance10%7% ↓
Clinical Intervention10%10%
Clinical Therapeutics20%18% ↓
Scientific Concepts10%7% ↓
Professional Practicenew—7%

Biggest content-area changes

  • Endocrine, neurologic, and renal/genitourinary content each rose from 8% to 10%.
  • Rheumatologic/musculoskeletal down from 12% to 8%.
  • Psychiatric/behavioral health added as a 5% content area.
  • The standalone Critical Care content area (7%) was removed (redistributed).
  • Diagnostic Studies (task area) up from 10% to 14%.
  • Professional Practice added at 7% (Health Maintenance retained at 7%).

Try 3 free Internal Medicine EOR questions

From the free Internal Medicine EOR practice page, mapped to this blueprint. Each one shows the correct answer and a full explanation; attempt it before you reveal the answer.

Question 1EndocrineMedium
A 62-year-old postmenopausal woman on levothyroxine 88 mcg daily for primary hypothyroidism has a TSH of 0.2 mIU/L with a normal free T4. She feels well and has no symptoms. Which of the following is the most appropriate next step?
  • ASwitch to desiccated thyroid extract
  • BContinue current dose
  • CDecrease levothyroxine dose
  • DIncrease levothyroxine dose
  • EAdd liothyronine
Reveal answer & full explanation
Correct answer: C — Decrease levothyroxine dose
  • ASwitch to desiccated thyroid extract
  • BContinue current dose
  • CDecrease levothyroxine dose✓
  • DIncrease levothyroxine dose
  • EAdd liothyronine

Why Decrease levothyroxine dose is correct

  • A suppressed TSH on levothyroxine increases the risk of atrial fibrillation and bone loss in postmenopausal women
  • The goal of levothyroxine replacement for hypothyroidism is a TSH within the reference range (about 0.4–4.0 mIU/L); this patient's TSH of 0.2 mIU/L is below it, and the ATA advises avoiding a subnormal TSH, especially in older and postmenopausal women, so reducing the dose is appropriate

Why the others are wrong

  • Add liothyronine — combination T3/T4 therapy is not routinely recommended and would not correct the over-replacement (trap)
  • Switch to desiccated thyroid extract — supraphysiologic T3 content and no advantage over levothyroxine; does not address the suppressed TSH (trap)
  • Increase levothyroxine dose — would further suppress TSH and worsen the risk of atrial fibrillation and bone loss (trap)
  • Continue current dose — tempting because she is asymptomatic with a normal free T4, but a subnormal TSH on levothyroxine is iatrogenic subclinical hyperthyroidism and still raises the risk of atrial fibrillation and bone loss (trap)
Question 2GastrointestinalMedium
A 22-year-old man is admitted to the internal medicine service after his second episode in 3 months of colicky periumbilical pain with vomiting that resolved on its own. He was adopted, and his biological family history is unknown. Hemoglobin is 9.6 g/dL, mean corpuscular volume is 72 fL, ferritin is 6 ng/mL, and stool is guaiac positive. CT obtained during the pain showed a transient jejunojejunal intussusception with a 2.5-cm intraluminal polyp at its lead point. Colonoscopy 2 days ago found only two small colonic polyps; pathology is pending. He is now pain free, and his vital signs are normal. Which additional physical examination finding is most likely?
  • ADiffuse uniform darkening of the palmar creases and the gums
  • BClusters of small dark-brown macules on lips and inner cheeks
  • CHard, painless bony swelling along the angle of the mandible
  • DSix or more oval tan patches over 1.5 cm with axillary freckling
  • ESeveral yellow-tan papules and nodules on the face and trunk
Reveal answer & full explanation
Correct answer: B — Clusters of small dark-brown macules on lips and inner cheeks
  • ADiffuse uniform darkening of the palmar creases and the gums
  • BClusters of small dark-brown macules on lips and inner cheeks✓
  • CHard, painless bony swelling along the angle of the mandible
  • DSix or more oval tan patches over 1.5 cm with axillary freckling
  • ESeveral yellow-tan papules and nodules on the face and trunk

Why Clusters of small dark-brown macules on lips and inner cheeks is correct

  • A young adult with recurrent small-bowel intussusception whose lead point is a large jejunal polyp, plus iron deficiency anemia from occult bleeding, points to Peutz-Jeghers syndrome, an autosomal dominant hamartomatous polyposis in which polyps cluster in the small bowel (jejunum most of all).
  • Its skin and mucosa marker is discrete, small (1-5 mm) dark-brown to blue-gray macules on the lips and buccal mucosa, often also around the mouth, nose and eyes and on the fingers and toes. Lip and skin macules may fade after puberty, but buccal pigment usually persists, so the inner cheeks are the place to look in an adult.
  • With the family history unavailable, the examination carries the diagnosis. Under the 2022 US Multi-Society Task Force on Colorectal Cancer (USMSTF) statement on gastrointestinal (GI) hamartomatous polyposis syndromes (Boland et al.), once the lead-point polyp is histologically confirmed as a Peutz-Jeghers polyp, Peutz-Jeghers polyps plus characteristic mucocutaneous pigmentation meet a clinical criterion for the syndrome. The polyp has not been resected yet, so the pigment supports the syndrome but is not a diagnosis on its own; germline STK11 testing is recommended.

Why the others are wrong

  • Hard, painless bony swelling along the angle of the mandible - Mandibular osteomas mark the Gardner variant of familial adenomatous polyposis (FAP), which produces hundreds to thousands of colorectal adenomas by early adulthood; a colonoscopy with only two small polyps argues against it, and a large jejunal polyp causing recurrent intussusception is not how FAP presents (the trap is reaching for the best-known polyposis syndrome).
  • Six or more oval tan patches over 1.5 cm with axillary freckling - These are the cafe-au-lait macules and skin-fold freckling of neurofibromatosis type 1 (NF1), found on the trunk and in the folds rather than on the lips or buccal mucosa; NF1 GI tumors, such as a gastrointestinal stromal tumor (GIST) or neurofibroma, arise beneath the mucosa, usually appear in middle age, and are not a hamartomatous polyposis (the trap is equating any pigmented macules or freckling with this syndrome).
  • Several yellow-tan papules and nodules on the face and trunk - Multiple sebaceous neoplasms, especially sebaceous adenomas and those arising off the head and neck such as on the trunk, suggest Muir-Torre syndrome, a Lynch syndrome variant; Lynch syndrome is not a polyposis syndrome, its colorectal and small-bowel cancers and its sebaceous tumors usually appear in middle age, and it is not expected to produce a large jejunal polyp that repeatedly telescopes in a 22-year-old (the trap is reaching for a hereditary colorectal cancer syndrome because a polyp was found).
  • Diffuse uniform darkening of the palmar creases and the gums - Diffuse, adrenocorticotropic hormone (ACTH)-driven pigmentation of the creases, gingiva and buccal mucosa suggests primary adrenal insufficiency (Addison disease), an endocrine disorder with no link to GI polyps, intussusception or occult GI bleeding (the trap is treating any oral pigmentation as the same sign; this syndrome's pigment is discrete macules, not diffuse darkening).

Additional high-yield points

  • Contrast the pigment patterns: discrete small macules on the lips and buccal mucosa (Peutz-Jeghers) versus diffuse darkening of the buccal mucosa, gums and palmar creases (Addison disease); cafe-au-lait macules with skin-fold freckling mark NF1.
  • Peutz-Jeghers syndrome carries a high lifetime cancer risk, including colorectal, gastric, small-bowel, pancreatic and breast cancer, so the 2022 USMSTF statement and the National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric guideline (2025/2026) call for scheduled upper endoscopy, colonoscopy and small-bowel imaging, plus pancreatic surveillance and, in women, breast surveillance in adulthood.
  • Large small-bowel polyps are removed electively (for example by device-assisted enteroscopy) to prevent intussusception and emergency laparotomy; first-degree relatives are offered genetic counseling and testing once a pathogenic variant is found.
Question 3NeurologyMedium
A 57-year-old man recovering from an ischemic stroke is preparing for discharge. He smokes cigarettes daily and asks for help quitting. He has no contraindication to standard cessation medications. Which prevention plan follows the United States Preventive Services Task Force (USPSTF) 2021 recommendation for nonpregnant adults aged 18 years or older?
  • AProvide electronic cigarettes as the preferred first cessation method
  • BProvide behavioral counseling and offer approved cessation medication
  • CProvide a plan to switch to lower-nicotine cigarettes before quitting
  • DProvide varenicline and defer counseling until after rehabilitation
  • EProvide cessation medication only after counseling has repeatedly failed
Reveal answer & full explanation
Correct answer: B — Provide behavioral counseling and offer approved cessation medication
  • AProvide electronic cigarettes as the preferred first cessation method
  • BProvide behavioral counseling and offer approved cessation medication✓
  • CProvide a plan to switch to lower-nicotine cigarettes before quitting
  • DProvide varenicline and defer counseling until after rehabilitation
  • EProvide cessation medication only after counseling has repeatedly failed

Why Provide behavioral counseling and offer approved cessation medication is correct

  • Continued smoking is a modifiable vascular risk in this adult stroke survivor.
  • Behavioral support and pharmacotherapy address behavioral reinforcement and nicotine dependence.
  • USPSTF 2021 gives a Grade A recommendation to counseling and approved pharmacotherapy for nonpregnant adults who smoke.

Why the others are wrong

  • Provide varenicline and defer counseling until after rehabilitation - USPSTF recommends behavioral interventions together with pharmacotherapy, and the combination achieves higher quit rates than either alone; counseling should not be postponed.
  • Provide a plan to switch to lower-nicotine cigarettes before quitting - Lower-nicotine cigarettes are not an FDA-approved cessation treatment, and smokers often compensate by smoking more intensely.
  • Provide cessation medication only after counseling has repeatedly failed - Medication does not require prior failure of repeated counseling attempts.
  • Provide electronic cigarettes as the preferred first cessation method - USPSTF found insufficient evidence to recommend electronic cigarettes for cessation.

Additional high-yield points

  • Arrange follow-up support after discharge, including a quitline if useful.
  • Select medication collaboratively based on contraindications, prior experience, and patient preference.

That's 3 of 7,700+. Get the rest.

Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial →

What to study now — free Internal Medicine resources

Practice the areas that carry more weight in 2026. These free FirstPassPA resources are mapped to the new blueprint:

Practice the 2026 Internal Medicine blueprint on FirstPassPA

Work a focused Internal Medicine question set, drawn from the full 7,700+ question bank, with an AI tutor on every answer. Start your 7-day free trial — no credit card.

Start studying free → Compare PANCE question banks

Internal Medicine EOR 2026 FAQ

What changed on the 2026 Internal Medicine EOR?

Endocrine, neurologic, and renal/GU content each rose to 10%, rheumatologic/MSK fell to 8%, psychiatric/behavioral health was added at 5%, the standalone Critical Care area was removed, Diagnostic Studies rose to 14%, and a 7% Professional Practice task area was added.

Source & disclaimer. Weightings are summarized from PAEA's publicly posted 2026 End of Rotation blueprints and crosswalk documents as of July 2026; PAEA is the authoritative source — always confirm current details there. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by PAEA or NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.